Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 105 | 2024 | 5649 | 4.950 |
Why?
|
Graft vs Host Disease | 88 | 2024 | 3025 | 4.890 |
Why?
|
Transplantation Conditioning | 45 | 2024 | 1588 | 2.690 |
Why?
|
Transplantation, Homologous | 60 | 2024 | 4810 | 2.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2021 | 1628 | 1.640 |
Why?
|
Hematologic Neoplasms | 30 | 2021 | 1895 | 1.360 |
Why?
|
Interleukin-2 | 13 | 2023 | 1889 | 1.130 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2024 | 3602 | 1.100 |
Why?
|
Leukemia, Promyelocytic, Acute | 9 | 2024 | 251 | 0.980 |
Why?
|
Myelodysplastic Syndromes | 10 | 2024 | 1394 | 0.870 |
Why?
|
Stem Cell Transplantation | 8 | 2021 | 1599 | 0.690 |
Why?
|
Cord Blood Stem Cell Transplantation | 7 | 2019 | 305 | 0.680 |
Why?
|
Recurrence | 31 | 2023 | 8482 | 0.650 |
Why?
|
Hepatic Veno-Occlusive Disease | 7 | 2022 | 221 | 0.630 |
Why?
|
Tacrolimus | 13 | 2023 | 733 | 0.620 |
Why?
|
T-Lymphocytes, Regulatory | 16 | 2022 | 3075 | 0.610 |
Why?
|
Lymphocyte Transfusion | 4 | 2021 | 232 | 0.520 |
Why?
|
Leukemia | 7 | 2024 | 1520 | 0.520 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1403 | 0.510 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1764 | 0.500 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 7 | 2013 | 263 | 0.450 |
Why?
|
Survival Analysis | 26 | 2019 | 10182 | 0.450 |
Why?
|
Sirolimus | 10 | 2019 | 1547 | 0.450 |
Why?
|
Adult | 119 | 2024 | 219994 | 0.440 |
Why?
|
Disease-Free Survival | 27 | 2018 | 6828 | 0.420 |
Why?
|
Myeloablative Agonists | 9 | 2018 | 209 | 0.410 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2221 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11712 | 0.400 |
Why?
|
Middle Aged | 116 | 2024 | 220352 | 0.390 |
Why?
|
Aged | 91 | 2024 | 169152 | 0.380 |
Why?
|
Steroids | 8 | 2023 | 928 | 0.380 |
Why?
|
Survival Rate | 17 | 2024 | 12808 | 0.370 |
Why?
|
Vidarabine | 8 | 2021 | 336 | 0.370 |
Why?
|
Lymphoma | 7 | 2017 | 1898 | 0.360 |
Why?
|
Busulfan | 9 | 2022 | 258 | 0.360 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2018 | 419 | 0.350 |
Why?
|
Endpoint Determination | 1 | 2013 | 597 | 0.340 |
Why?
|
Graft Survival | 10 | 2014 | 3794 | 0.330 |
Why?
|
BK Virus | 2 | 2020 | 123 | 0.320 |
Why?
|
Humans | 166 | 2024 | 760621 | 0.320 |
Why?
|
Recovery of Function | 2 | 2019 | 2985 | 0.310 |
Why?
|
Young Adult | 51 | 2024 | 58741 | 0.310 |
Why?
|
B-Cell Activating Factor | 5 | 2014 | 115 | 0.310 |
Why?
|
Myeloproliferative Disorders | 5 | 2022 | 609 | 0.310 |
Why?
|
Graft vs Leukemia Effect | 3 | 2020 | 121 | 0.310 |
Why?
|
T-Lymphocytes | 8 | 2021 | 10181 | 0.310 |
Why?
|
Methotrexate | 12 | 2018 | 1719 | 0.310 |
Why?
|
Male | 120 | 2024 | 359744 | 0.300 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 861 | 0.300 |
Why?
|
Transplantation, Autologous | 10 | 2022 | 2116 | 0.290 |
Why?
|
Antilymphocyte Serum | 3 | 2018 | 482 | 0.290 |
Why?
|
Killer Cells, Natural | 8 | 2022 | 2203 | 0.290 |
Why?
|
Female | 120 | 2024 | 391270 | 0.280 |
Why?
|
Chronic Disease | 26 | 2023 | 9287 | 0.280 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2022 | 4550 | 0.280 |
Why?
|
Iron Overload | 4 | 2014 | 240 | 0.280 |
Why?
|
Gene Expression Regulation, Leukemic | 3 | 2021 | 646 | 0.270 |
Why?
|
Leukocyte Count | 5 | 2019 | 1600 | 0.260 |
Why?
|
Quinazolinones | 2 | 2019 | 223 | 0.260 |
Why?
|
Leukocytes | 1 | 2014 | 2026 | 0.260 |
Why?
|
Immunosuppressive Agents | 10 | 2018 | 4166 | 0.260 |
Why?
|
Neoplasm, Residual | 4 | 2022 | 1007 | 0.250 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2021 | 1375 | 0.250 |
Why?
|
Fetal Blood | 5 | 2019 | 1343 | 0.240 |
Why?
|
Prognosis | 27 | 2021 | 29658 | 0.240 |
Why?
|
Purines | 2 | 2019 | 605 | 0.230 |
Why?
|
Retrospective Studies | 47 | 2024 | 80372 | 0.230 |
Why?
|
T-Lymphocyte Subsets | 4 | 2019 | 1810 | 0.230 |
Why?
|
Adolescent | 42 | 2024 | 87810 | 0.230 |
Why?
|
Treatment Outcome | 44 | 2024 | 65017 | 0.220 |
Why?
|
Leukemia, Myeloid | 5 | 2021 | 695 | 0.220 |
Why?
|
Lymphocyte Count | 5 | 2019 | 780 | 0.210 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2017 | 1547 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Sex Factors | 2 | 2016 | 10547 | 0.210 |
Why?
|
Chromosome Deletion | 2 | 2018 | 1387 | 0.210 |
Why?
|
Daunorubicin | 5 | 2015 | 156 | 0.200 |
Why?
|
Ferritins | 5 | 2014 | 597 | 0.200 |
Why?
|
Antigens, CD34 | 1 | 2024 | 653 | 0.200 |
Why?
|
Models, Biological | 2 | 2015 | 9467 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2020 | 4353 | 0.200 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 693 | 0.190 |
Why?
|
Tretinoin | 6 | 2015 | 519 | 0.190 |
Why?
|
HLA Antigens | 5 | 2017 | 1368 | 0.190 |
Why?
|
Proportional Hazards Models | 4 | 2015 | 12531 | 0.180 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 124 | 0.180 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 210 | 0.180 |
Why?
|
Treatment Failure | 2 | 2024 | 2648 | 0.180 |
Why?
|
Boronic Acids | 3 | 2014 | 914 | 0.180 |
Why?
|
Immunotherapy, Adoptive | 3 | 2021 | 1454 | 0.180 |
Why?
|
Models, Theoretical | 1 | 2012 | 3562 | 0.170 |
Why?
|
Smallpox Vaccine | 2 | 2010 | 77 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 264 | 0.170 |
Why?
|
Dioxygenases | 1 | 2021 | 335 | 0.170 |
Why?
|
Drug Resistance | 3 | 2019 | 1617 | 0.160 |
Why?
|
DNA, Mitochondrial | 1 | 2024 | 858 | 0.160 |
Why?
|
Lymphocyte Activation | 6 | 2022 | 5496 | 0.160 |
Why?
|
Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
Transplantation Chimera | 4 | 2015 | 595 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 12 | 2021 | 6544 | 0.160 |
Why?
|
Pyrazines | 3 | 2014 | 1199 | 0.160 |
Why?
|
Long QT Syndrome | 1 | 2023 | 466 | 0.160 |
Why?
|
Incidence | 12 | 2023 | 21392 | 0.160 |
Why?
|
Vaccinia virus | 2 | 2010 | 331 | 0.150 |
Why?
|
Combined Modality Therapy | 7 | 2021 | 8552 | 0.150 |
Why?
|
Piperidines | 3 | 2021 | 1650 | 0.150 |
Why?
|
Lymphocyte Depletion | 3 | 2016 | 602 | 0.150 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9585 | 0.150 |
Why?
|
Acute Disease | 11 | 2024 | 7269 | 0.150 |
Why?
|
Tissue Donors | 10 | 2024 | 2313 | 0.140 |
Why?
|
Immunoglobulins | 2 | 2017 | 859 | 0.140 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.140 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 305 | 0.140 |
Why?
|
Polyomavirus Infections | 1 | 2019 | 194 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1977 | 0.140 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 124 | 0.140 |
Why?
|
Age Factors | 9 | 2024 | 18416 | 0.140 |
Why?
|
Tumor Virus Infections | 1 | 2019 | 438 | 0.130 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 68 | 0.130 |
Why?
|
Bone Marrow Transplantation | 4 | 2023 | 2693 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 191 | 0.130 |
Why?
|
Lymphoma, Follicular | 1 | 2020 | 453 | 0.130 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2018 | 237 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3610 | 0.130 |
Why?
|
Research Design | 1 | 2012 | 6180 | 0.130 |
Why?
|
Histocompatibility Testing | 6 | 2015 | 717 | 0.130 |
Why?
|
Skin Diseases | 3 | 2020 | 1089 | 0.130 |
Why?
|
Pyrazoles | 3 | 2024 | 1999 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2017 | 1407 | 0.130 |
Why?
|
Blood Donors | 3 | 2013 | 343 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 10344 | 0.120 |
Why?
|
Prednisone | 3 | 2018 | 1565 | 0.120 |
Why?
|
Stem Cell Factor | 1 | 2015 | 196 | 0.120 |
Why?
|
Interleukin-7 | 1 | 2015 | 142 | 0.120 |
Why?
|
Immunologic Memory | 3 | 2017 | 1354 | 0.120 |
Why?
|
H-Y Antigen | 2 | 2004 | 42 | 0.120 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 581 | 0.120 |
Why?
|
Sequence Deletion | 1 | 2018 | 1493 | 0.120 |
Why?
|
Isoantibodies | 3 | 2009 | 661 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1319 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2016 | 1745 | 0.110 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
Pyrimidines | 3 | 2024 | 3016 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2919 | 0.110 |
Why?
|
Tandem Repeat Sequences | 1 | 2014 | 180 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1608 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9276 | 0.110 |
Why?
|
Aged, 80 and over | 13 | 2019 | 58995 | 0.110 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39261 | 0.100 |
Why?
|
Histocompatibility | 2 | 2012 | 316 | 0.100 |
Why?
|
Viremia | 2 | 2019 | 707 | 0.100 |
Why?
|
Whole-Body Irradiation | 2 | 2018 | 433 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2828 | 0.100 |
Why?
|
Antibodies, Monoclonal | 5 | 2022 | 9185 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
Homeostasis | 3 | 2013 | 3306 | 0.100 |
Why?
|
Pulmonary Edema | 2 | 2014 | 409 | 0.100 |
Why?
|
B-Lymphocytes | 4 | 2014 | 4742 | 0.100 |
Why?
|
Comorbidity | 2 | 2019 | 10551 | 0.100 |
Why?
|
Remission Induction | 6 | 2019 | 2392 | 0.090 |
Why?
|
Minor Histocompatibility Antigens | 2 | 2010 | 293 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 995 | 0.090 |
Why?
|
Community Networks | 1 | 2013 | 201 | 0.090 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 362 | 0.090 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 264 | 0.090 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2014 | 495 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1941 | 0.090 |
Why?
|
Antineoplastic Agents | 6 | 2017 | 13630 | 0.090 |
Why?
|
Salvage Therapy | 3 | 2012 | 1268 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 975 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1091 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4283 | 0.090 |
Why?
|
Tissue Preservation | 1 | 2011 | 174 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2008 | 1378 | 0.090 |
Why?
|
Mutation | 7 | 2024 | 29932 | 0.090 |
Why?
|
Adenine | 3 | 2021 | 975 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4713 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1869 | 0.080 |
Why?
|
Cohort Studies | 12 | 2018 | 41335 | 0.080 |
Why?
|
Erythema | 1 | 2010 | 262 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2017 | 5870 | 0.080 |
Why?
|
Immunophenotyping | 5 | 2016 | 1871 | 0.080 |
Why?
|
Chromosomes, Human, Y | 1 | 2010 | 162 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 685 | 0.080 |
Why?
|
Iron | 3 | 2014 | 1786 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 968 | 0.080 |
Why?
|
Time Factors | 11 | 2021 | 40165 | 0.080 |
Why?
|
Premedication | 2 | 2008 | 253 | 0.080 |
Why?
|
Antibodies | 2 | 2017 | 2421 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 316 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1088 | 0.070 |
Why?
|
Multiple Myeloma | 2 | 2021 | 5130 | 0.070 |
Why?
|
Lymphoproliferative Disorders | 1 | 2011 | 533 | 0.070 |
Why?
|
B-Lymphocyte Subsets | 1 | 2009 | 241 | 0.070 |
Why?
|
Prospective Studies | 12 | 2022 | 54303 | 0.070 |
Why?
|
Thymus Gland | 2 | 2010 | 1247 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 2 | 2011 | 3387 | 0.070 |
Why?
|
Fever | 2 | 2014 | 1617 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12159 | 0.070 |
Why?
|
Core Binding Factors | 1 | 2006 | 29 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 626 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4466 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 198 | 0.070 |
Why?
|
Telomerase | 1 | 2011 | 746 | 0.070 |
Why?
|
Risk | 5 | 2011 | 9631 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 824 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5643 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 2010 | 755 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 2802 | 0.060 |
Why?
|
Antigens, CD1 | 1 | 2008 | 439 | 0.060 |
Why?
|
Idarubicin | 2 | 2015 | 59 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 649 | 0.060 |
Why?
|
Algorithms | 2 | 2024 | 13981 | 0.060 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2005 | 106 | 0.060 |
Why?
|
Living Donors | 1 | 2009 | 636 | 0.060 |
Why?
|
Integrins | 1 | 2009 | 839 | 0.060 |
Why?
|
Antigens, CD | 4 | 2022 | 4000 | 0.060 |
Why?
|
Intestinal Diseases | 1 | 2009 | 506 | 0.060 |
Why?
|
Hematologic Diseases | 2 | 2019 | 496 | 0.060 |
Why?
|
Risk Factors | 10 | 2018 | 74359 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1155 | 0.060 |
Why?
|
Vaccination | 2 | 2022 | 3361 | 0.060 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2004 | 58 | 0.060 |
Why?
|
Syndrome | 3 | 2018 | 3280 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1864 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 1 | 2011 | 1827 | 0.060 |
Why?
|
Receptors, Interleukin-2 | 1 | 2005 | 562 | 0.060 |
Why?
|
Risk Assessment | 4 | 2019 | 24123 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 2010 | 831 | 0.050 |
Why?
|
Developing Countries | 2 | 2013 | 2868 | 0.050 |
Why?
|
Dendritic Cells | 1 | 2014 | 2725 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 886 | 0.050 |
Why?
|
Cryopreservation | 2 | 2021 | 717 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2021 | 12427 | 0.050 |
Why?
|
Child | 9 | 2023 | 79806 | 0.050 |
Why?
|
Uruguay | 2 | 2013 | 104 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1032 | 0.050 |
Why?
|
Diet | 1 | 2021 | 8010 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7064 | 0.050 |
Why?
|
Blood Platelets | 1 | 2013 | 2520 | 0.050 |
Why?
|
Stomatitis | 1 | 2005 | 271 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
Mouth Mucosa | 1 | 2005 | 426 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2019 | 2536 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 334 | 0.050 |
Why?
|
United States | 4 | 2021 | 72461 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10446 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4490 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15840 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5125 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2475 | 0.050 |
Why?
|
Transplantation Immunology | 2 | 2016 | 532 | 0.050 |
Why?
|
Neoplasms | 2 | 2007 | 22072 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3600 | 0.050 |
Why?
|
Cytokines | 3 | 2021 | 7343 | 0.050 |
Why?
|
Melphalan | 1 | 2022 | 420 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 138 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5791 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2006 | 1388 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2012 | 5253 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 899 | 0.040 |
Why?
|
Injections, Intradermal | 2 | 2010 | 116 | 0.040 |
Why?
|
Mexico | 2 | 2013 | 760 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2010 | 365 | 0.040 |
Why?
|
Antibody Formation | 2 | 2017 | 1400 | 0.040 |
Why?
|
Disease Progression | 5 | 2016 | 13502 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 3047 | 0.040 |
Why?
|
Nitriles | 1 | 2024 | 956 | 0.040 |
Why?
|
Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2003 | 918 | 0.040 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2018 | 57 | 0.040 |
Why?
|
Vaccines, Attenuated | 2 | 2010 | 314 | 0.040 |
Why?
|
Injections, Intramuscular | 2 | 2010 | 553 | 0.040 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 76 | 0.040 |
Why?
|
Brazil | 2 | 2013 | 1218 | 0.040 |
Why?
|
Antibodies, Viral | 3 | 2019 | 3143 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2852 | 0.040 |
Why?
|
Forkhead Transcription Factors | 3 | 2011 | 1612 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4433 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3157 | 0.040 |
Why?
|
Quality Improvement | 1 | 2013 | 3836 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6360 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2018 | 384 | 0.040 |
Why?
|
Administration, Oral | 2 | 2019 | 4035 | 0.040 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 929 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 877 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 967 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2696 | 0.030 |
Why?
|
Spleen | 1 | 2023 | 2298 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6465 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 113 | 0.030 |
Why?
|
Immune Tolerance | 2 | 2019 | 2299 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3334 | 0.030 |
Why?
|
Karyotyping | 2 | 2011 | 1171 | 0.030 |
Why?
|
Chromosome Breakage | 1 | 2016 | 159 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1837 | 0.030 |
Why?
|
Antibody Specificity | 2 | 2011 | 1060 | 0.030 |
Why?
|
Immunotherapy | 2 | 2023 | 4642 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2145 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2016 | 2506 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 877 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2627 | 0.030 |
Why?
|
Food Supply | 1 | 2021 | 542 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2016 | 18957 | 0.030 |
Why?
|
Matched-Pair Analysis | 1 | 2015 | 284 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2014 | 22053 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2014 | 27 | 0.030 |
Why?
|
Lymphocytes | 2 | 2014 | 2611 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 830 | 0.030 |
Why?
|
Interleukin-17 | 1 | 2020 | 910 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 777 | 0.030 |
Why?
|
Aging | 2 | 2010 | 8651 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 172 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2380 | 0.030 |
Why?
|
Infant | 3 | 2023 | 36060 | 0.030 |
Why?
|
Liver | 3 | 2016 | 7509 | 0.030 |
Why?
|
Latin America | 1 | 2014 | 404 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1660 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3804 | 0.030 |
Why?
|
Child, Preschool | 3 | 2023 | 42063 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 591 | 0.030 |
Why?
|
DNA, Viral | 1 | 2019 | 2194 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2012 | 15697 | 0.030 |
Why?
|
Chile | 1 | 2013 | 255 | 0.030 |
Why?
|
Models, Statistical | 1 | 2007 | 5075 | 0.030 |
Why?
|
Anthracyclines | 1 | 2014 | 283 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2016 | 1342 | 0.020 |
Why?
|
Gene Dosage | 1 | 2016 | 1218 | 0.020 |
Why?
|
Saliva | 1 | 2016 | 820 | 0.020 |
Why?
|
Death | 1 | 2016 | 678 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2007 | 8515 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7588 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4899 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8555 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2015 | 1697 | 0.020 |
Why?
|
Interleukin-4 | 1 | 2014 | 1130 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 248 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 6898 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
Antibodies, Neutralizing | 2 | 2010 | 1933 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2569 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10827 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14495 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Genetic Testing | 1 | 2003 | 3531 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2514 | 0.020 |
Why?
|
Virus Shedding | 1 | 2010 | 111 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 225 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2010 | 211 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2010 | 105 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 787 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3523 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1915 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2010 | 344 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 600 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 680 | 0.020 |
Why?
|
Proteins | 1 | 2003 | 6029 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 696 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 354 | 0.020 |
Why?
|
Hemoglobins | 1 | 2014 | 1521 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 1841 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 229 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1895 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 576 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6377 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9501 | 0.020 |
Why?
|
Antigens, CD1d | 1 | 2008 | 217 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1004 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2803 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2007 | 271 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1126 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2013 | 2414 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1596 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2010 | 673 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2128 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11152 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8313 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3602 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4541 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 820 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1500 | 0.020 |
Why?
|
Serologic Tests | 1 | 2007 | 383 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 2913 | 0.010 |
Why?
|
Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
Temperature | 1 | 2011 | 2221 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2005 | 641 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6551 | 0.010 |
Why?
|
Drug Therapy, Combination | 2 | 2004 | 6498 | 0.010 |
Why?
|
Consensus | 1 | 2013 | 3113 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23376 | 0.010 |
Why?
|
Drug Combinations | 1 | 2008 | 2025 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14660 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1720 | 0.010 |
Why?
|
Autoantibodies | 1 | 2010 | 2118 | 0.010 |
Why?
|
Bone Marrow | 1 | 2012 | 2912 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81208 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8624 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 8056 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14372 | 0.010 |
Why?
|
Cell Survival | 1 | 2011 | 5797 | 0.010 |
Why?
|
DEAD-box RNA Helicases | 1 | 2003 | 383 | 0.010 |
Why?
|
Up-Regulation | 1 | 2009 | 4122 | 0.010 |
Why?
|
Education, Medical | 1 | 2012 | 1727 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2003 | 1991 | 0.010 |
Why?
|
Musculoskeletal Diseases | 1 | 2006 | 595 | 0.010 |
Why?
|
Risk Management | 1 | 2003 | 558 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20080 | 0.010 |
Why?
|
Myocardium | 1 | 2012 | 4700 | 0.010 |
Why?
|
Graft Rejection | 1 | 2011 | 4426 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18137 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9411 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2010 | 3539 | 0.010 |
Why?
|
Epitopes | 1 | 2003 | 2503 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15789 | 0.010 |
Why?
|
Animals | 2 | 2020 | 167963 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2003 | 2362 | 0.010 |
Why?
|
Reoperation | 1 | 2006 | 4291 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9280 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11071 | 0.010 |
Why?
|
Educational Status | 1 | 2003 | 2515 | 0.010 |
Why?
|
Attitude to Health | 1 | 2004 | 2029 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 2414 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36290 | 0.010 |
Why?
|
Women's Health | 1 | 2003 | 2056 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2004 | 2628 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2003 | 2629 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12446 | 0.010 |
Why?
|
Survivors | 1 | 2003 | 2375 | 0.010 |
Why?
|
Health Behavior | 1 | 2003 | 2622 | 0.010 |
Why?
|
Length of Stay | 1 | 2005 | 6479 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5209 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3865 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 25942 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11481 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2003 | 3986 | 0.000 |
Why?
|
Phenotype | 1 | 2005 | 16546 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 11903 | 0.000 |
Why?
|
Physicians | 1 | 2004 | 4591 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2003 | 4878 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15757 | 0.000 |
Why?
|
Depression | 1 | 2003 | 8044 | 0.000 |
Why?
|
Quality of Life | 1 | 2004 | 13308 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 21025 | 0.000 |
Why?
|